Britain and America have announced a major trade agreement that will guarantee zero import taxes on British drug products entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has committed to raise expenditure on medicines through the NHS. This move secures that duties on these crucial products will be held at nothing for a duration of three years.
This development comes after recent warnings to hike tariffs on patented drug products, with increases floated as high as one hundred percent.
"This deal with the United Kingdom strengthens the global environment for new treatments and introduces much-needed fairness to American-British medicine commerce," an announcement noted.
Commercial Impact
Medicines represent one of the UK's largest exports to the US, which is easily the largest market for leading companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of September, the UK shipped medicines worth £11.1bn to the US. This amount accounted for 17.4% of all goods exports in that period.
"This guarantee secures employment, stimulates funding and paves the way for the UK to become a international leader for life sciences," a government official stated.
Detailed British Pledges
The deal entails several key changes from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it considers new medicines to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to raise overall public funding on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The sum manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates were more than 20%.
Broader Context
This agreement comes amid a protracted row between the drug companies and the ministers over drug pricing and NHS adoption.
The disagreement were heightened by arguments that American consumers were paying significantly more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or cancelled, while substantial investments have been directed toward US facilities.
A senior figure acknowledged that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had shrunk as a proportion of its resources over the last ten years.
